Inclisiran: A Jab Goes a Long Way
High levels of low-density lipoprotein (LDL) cholesterol can increase the risk of atherosclerosis and cardiovascular events such as a heart attack or stroke. Inclisiran, now approved by NICE (2021) can be used to reduce LDL cholesterol.
Do you know when, how and on which patients to use the novel anti-cholesterol drug inclisiran to treat elevated LDL in patients with hypercholesterolaemia, mixed dyslipidaemia or patients that have had a previous cardiovascular event?
Join our webinar and learn more during an interactive panel discussion, showcasing real-world case applications of this new agent, produced as part of the ISCP series on the A to Z of CV Pharmacotherapy.
Led by moderators Dr Krittin Bunditakanul (Bangkok, Thailand) and Dr Doreen Tan (Singapore), it includes a speaker presentation from Prof Kyzysztof Filipiak (Warsaw, Poland), two case presentations from Dr Bundaitakanul and discussions from panellists Prof Bernard Cheung (Hong Kong) and Dr Alberto Lorensatti (Argentina) that will examine the considerations for use of this new agent, through interesting real-world examples, live discussions and audience Q&A.
This live webinar is EBAC accredited. 1 CME credit will be granted upon confirmation of successful attendance.
Bernard Man Yung Cheung
Doreen Su-Yin Tan
This webinar is an independent activity ran by the International Society of Cardiovascular Pharmacotherapy (ISCP):
Key Learning Objectives
- To evaluate and understand which patients should and should not receive inclisiran and which patients groups might benefit most
- To determine how inclisiran should be administered and what dosage adjustments, drug interactions or pharmacogenetic issues need to be noted
- To analyse special and regional issues that impact the use of this agent and evaluate which groups will benefit most
- To apply evidence-based recommendations to two real world cases
- Cardiovascular team members - doctors, nurses and pharmacists
- Family physicians
- Healthcare students
- Cardiovascular pharmacotherapy researchers
Specialist in: cardiology, internal medicine, arterial hypertension, clinical pharmacology (4 certified specializations).
Education: Medical University of Warsaw (MUW), MD, PhD.
Scientific and clinical internships: Medical Faculty, Utrecht University, Netherlands, Medical Faculty, Amsterdam University, Netherlands, Internal Medicine Department, Gaffree e Guinle University, Rio de Janeiro, Brazil, Department of Pharmacology, University of Geneva, Switzerland; Erasmus Programme for University Teachers' Exchange, Milan, Italy; University of Nis, Serbia: visiting professor.
Affiliations: Maria Sklodowska-Curie Medical Academy in Warsaw – Professor and Rector Magnificus since 2021; former: MUW Vice Dean for Science, Medical Faculty 2012-16; Deputy Rector Magnificus, MUW 2016-19; Dean for Science/Medical Sciences Council Chairman in MUW 2019-20;
Medical association memberships: Polish Cardiac Society (PCS): Chairman of Polish Top Junior Cardiologists ,,Club 30” 2007-09; Co-founder and first Chairman of PCS Cardiovascular Pharmacotherapy Working Group 2010-13; Polish Society of Hypertension: President 2018-20; Past-President 2020-22; International Society of Cardiovascular Pharmacotherapy – Governor for Poland 2016 -; European Society of Cardiology - member of the Working Group on Acute Cardiac Care and the Working Group on Cardiovascular Pharmacotherapy; Fellow of European Society of Cardiology 2009;
Research interests: dyslipidaemias, acute coronary syndromes, heart failure, stable angina, cardiovascular pharmacotherapy, renin-angiotensin system, platelets, coagulation, post-COVID, LONG COVID syndromes.
Papers: over 550 indexed in PubMed MEDLINE; according to Google Scholar database (April, 2022): 8016 citations, Hirsch index = 41; i-10 index = 194.
Textbooks: Author and co-author about 100 chapters in monographs and textbooks; co-author and co-editor in Polish e.g.: [Renin-Angiotensin System Drugs], Opolski G, Filipiak KJ, eds., 2000; [Statins - The Basic Clinical Pharmacology], Filipiak KJ, Opolski G, eds., 2001; [Acute Coronary Syndromes], Opolski G, Filipiak KJ, Polonski L, eds., 2002; [Hypertension in oncology], Filipiak KJ, Szymanski FM, Szmit S, eds., 2018. [Coronavirus SARS-CoV-2 textbook], Dzieciatkowski T, Filipiak KJ, eds., 2021.
Former Editor-in-chief (2012-2017): Kardiologia Polska [Polish Heart Journal] – the official journal of Polish Cardiac Society, Executive Editor Cardiology Journal (since 2018-); Editorial Board member of Journal of Cardivascular Development and Disease (IF=3,948).
Tutor experience: 22 PhD, including 12 PhD with special distinction; 12 specialists in cardiology, 7 specialists in internal medicine; reviewer of 56 PhD theses.
Clinical trials experience: ALIVE, ONTARGET/TRANSCEND, IMRPOVE-IT, SIGNIFY, Q-SYMBIO.
Bernard Man Yung Cheung
Dr Alberto J. Lorenzatti heads the Lipid Clinic & Cardiovascular Prevention – Cardiology Department – Hospital Córdoba (Cordoba-Argentina). He also is Co-Director at the DAMIC Medical Institute / Rusculleda Foundation for Research, Teaching and Patient Care (Clinical Research network with more than 50 research sites in Argentina).
University Degrees: Medical Doctor- National Córdoba University, School of Medicine 1980. Specialist in Cardiology - National Córdoba University - 1988. Certified Clinical Lipidologist - Argentine Lipid Society 2014
Academic Background: Invited Professor of Internal Medicine, Universidad Nacional de Córdoba (Argentina), Teacher of Postgraduate Training in Cardiology, Córdoba National University, Hospital Córdoba.
Dr Alberto Lorenzatti is Section Editor of European Cardiology Review.
Dr. Krittin has 15 years’ experience in pharmacy practice, with special interest in cardiovascular, diabetes, emergency, critical care and community pharmacy.
Education: Bachelor of Pharmacy at Huachiew Chalermprakiet University, Doctor of Pharmacy at Chulalongkorn University both located in Thailand.
Training experience: University of Arizona on 2009 and short course training for Emergency and Critical care pharmacotherapy at Kansas in 2014.
Professional affiliation: Committee of College of Pharmacotherapy, Thailand, Committee of Community of Pharmacist for Heart and Vascular, vice president of community pharmacy association of Thailand.
Doreen Su-Yin Tan
Doreen Tan is an Associate Professor of Clinical & Pharmacy Practice at the National University of Singapore. For further information please review her biography in full here: https://pharmacy.nus.edu.sg/team/a-prof-doreen-tan-su-yin/